Pharmacology & Therapeutics

Article	Citations
Tumor microenvironment as a therapeutic target in cancer	827
Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms	319
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development	291
The mechanism of action of N-acetylcysteine (NAC): The emerging role of H2S and sulfane sulfur species	204
Resolution of inflammation: An organizing principle in biology and medicine	182
Advances in pathogenesis and therapeutic strategies for osteoporosis	176
The birth of artemisinin	176
Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression	170
Programming inflammatory cell death for therapy	143
Targeting autophagy in ischemic stroke: From molecular mechanisms to clinical therapeutics	135
Bile acid metabolism and signaling, the microbiota, and metabolic disease	131
The strategies and techniques of drug discovery from natural products	130
Therapeutic targets in lung tissue remodelling and fibrosis	127
Natural medicine in neuroprotection for ischemic stroke: Challenges and prospective	124
Targeting the NLRP3 inflammasome in cardiovascular diseases	118
Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment	117
Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint	117
Carcinogenesis: Failure of resolution of inflammation?	115
Traditional application and modern pharmacological research of Artemisia annua L.	106
Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics	104
Molecular mechanisms of ferroptosis and their involvement in brain diseases	103
Evidence-based pharmacological treatment options for ADHD in children and adolescents	99
PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders	99
Drug repurposing for COVID-19: Approaches, challenges and promising candidates	97
The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy	95

Macrophage migration inhibitory factor (MIF): A multifaceted cytokine regulated by genetic and physiological strategies	94
Chinmedomics, a new strategy for evaluating the therapeutic efficacy of herbal medicines	93
Role of inflammatory chemokines in hypertension	86
Polyphenols and neuroprotection: Therapeutic implications for cognitive decline	85
Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms	85
The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications	85
Stepping forward in antibody-drug conjugate development	85
Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options	84
Gut dysbiosis, defective autophagy and altered immune responses in neurodegenerative diseases: Tales of a vicious cycle	81
CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases	79
Updates on community acquired pneumonia management in the ICU	78
Kynurenine emerges from the shadows – Current knowledge on its fate and function	78
The central role of IL-33/IL-1RL1 pathway in asthma: From pathogenesis to intervention	78
Current developments of targeting the p53 signaling pathway for cancer treatment	77
A decade of cell death studies: Breathing new life into necroptosis	76
Pharmacological treatment of eating disorders, comorbid mental health problems, malnutrition and physical health consequences	74
The Role of non-coding RNAs in colorectal cancer, with a focus on its autophagy	73
Tumor organoid models in precision medicine and investigating cancer-stromal interactions	73
Fight fire with fire: Neurobiology of capsaicin-induced analgesia for chronic pain	73
Circular RNAs are a novel type of non-coding RNAs in ROS regulation, cardiovascular metabolic inflammations and cancers	71
Targeting post-translational histone modifying enzymes in glioblastoma	70
Short-chain fatty acid receptors and gut microbiota as therapeutic targets in metabolic, immune, and neurological diseases	70
Metal-dependent Ser/Thr protein phosphatase PPM family: Evolution, structures, diseases and inhibitors	68
Extracellular vesicles in cardiovascular disease: Biological functions and therapeutic implications	68
Macrophage immunometabolism in inflammatory bowel diseases: From pathogenesis to therapy	68
Sirtuins' control of autophagy and mitophagy in cancer	68
Immune activities of polysaccharides isolated from Lycium barbarum L. What do we know so far?	66
Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials	65
Genotoxic therapy and resistance mechanism in gliomas	62
Cell plasticity, senescence, and quiescence in cancer stem cells: Biological and therapeutic implications	62
Myeloperoxidase: Mechanisms, reactions and inhibition as a therapeutic strategy in inflammatory diseases	62
TGFβ-Directed Therapeutics: 2020	61
G-quadruplex-based aptamers targeting human thrombin: Discovery, chemical modifications and antithrombotic effects	61
Particulate matter air pollutants and cardiovascular disease: Strategies for intervention	61
Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression	60
Novel strategies exploiting interleukin-12 in cancer immunotherapy	59
GABAkines – Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors	58
Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization	58
Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics	57
Review: RNA-based diagnostic markers discovery and therapeutic targets development in cancer	57
Treatment of overdose in the synthetic opioid era	57
Current and emerging therapies for Duchenne muscular dystrophy and spinal muscular atrophy	57
Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing	56
Evolving roles of lysyl oxidase family in tumorigenesis and cancer therapy	56
Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19	56
A deep dive into UV-based phototherapy: Mechanisms of action and emerging molecular targets in inflammation and cancer	56
Endothelial shear stress signal transduction and atherogenesis: From mechanisms to therapeutics	55
Probiotics: Potential novel therapeutics for microbiota-gut-brain axis dysfunction across gender and lifespan	55
Antimicrobial peptides – Unleashing their therapeutic potential using nanotechnology	55
Advances in the research on the targets of anti-malaria actions of artemisinin	55

FK506 binding proteins and inflammation related signalling pathways; basic biology, current status and future prospects for pharmacological intervention	55
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets	54
Vasculogenic mimicry, a complex and devious process favoring tumorigenesis – Interest in making it a therapeutic target	54
Clinical therapies and nano drug delivery systems for urinary bladder cancer	53
Therapeutic potential of targeting G protein-gated inwardly rectifying potassium (GIRK) channels in the central nervous system	52
Toxicology of flavoring- and cannabis-containing e-liquids used in electronic delivery systems	52
Blood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance	51
Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination	51
Metabolomics, metabolic flux analysis and cancer pharmacology	50
Enhancing autophagy in Alzheimer's disease through drug repositioning	50
Inflammation in kidney repair: Mechanism and therapeutic potential	49
Targeting the crosstalk between canonical Wnt/β-catenin and inflammatory signaling cascades: A novel strategy for cancer prevention and therapy	49
Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications?	49
Targeting BET bromodomain proteins in cancer: The example of lymphomas	48
Resolving inflammation by TAM receptor activation	48
Extracellular vesicles in cancer diagnostics and therapeutics	48
Regulation of organic anion transporters: Role in physiology, pathophysiology, and drug elimination	48
Cyclooxygenases and the cardiovascular system	47
The role of CD71+ erythroid cells in the regulation of the immune response	47
SARS-CoV-2 and other coronaviruses negatively influence mitochondrial quality control: beneficial effects of melatonin	47
Functional metabolomics innovates therapeutic discovery of traditional Chinese medicine derived functional compounds	46
Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach	46
The regulation of PKA signaling in obesity and in the maintenance of metabolic health	45
Dietary nutrition for neurological disease therapy: Current status and future directions	45
Physiology and pharmacology of amyloid precursor protein	45
A natural products solution to diabetic nephropathy therapy	44
Peroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis	44
Signal transduction in primary cilia – analyzing and manipulating GPCR and second messenger signaling	43
Current state and future perspective of cardiovascular medicines derived from natural products	43
Myeloperoxidase: Growing importance in cancer pathogenesis and potential drug target	42
Natural products targeting mitochondria: emerging therapeutics for age-associated neurological disorders	42
In cancer, all roads lead to NADPH	42
Myeloperoxidase: A versatile mediator of endothelial dysfunction and therapeutic target during cardiovascular disease	41
G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs)	40
Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders	40
Stem cell therapy in liver regeneration: Focus on mesenchymal stem cells and induced pluripotent stem cells	40
Anti-cancer activity of sustained release capsaicin formulations	40
TSLP as druggable target – a silver-lining for atopic diseases?	39
The chemistry and toxicology of vaping	39
Deciphering the key heterocyclic scaffolds in targeting microtubules, kinases and carbonic anhydrases for cancer drug development	39
Mitochondrial K+ channels and their implications for disease mechanisms	39
The emerging role of leukemia inhibitory factor in cancer and therapy	39
The therapeutic potential of Nrf2 inducers in chronic pain: Evidence from preclinical studies	39
Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities	38
Nanomedicine: Photo-activated nanostructured titanium dioxide, as a promising anticancer agent	38
The gut microbiome and efficacy of cancer immunotherapy	38
Glycoprotein VI - novel target in antiplatelet medication	38
Therapeutic potential of the target on NLRP3 inflammasome in multiple sclerosis	38
Functional hydrogels as therapeutic tools for spinal cord injury: New perspectives on immunopharmacological interventions	38
Functional and Biochemical Consequences of Disease Variants in Neurotransmitter Transporters: A Special Emphasis on Folding and Trafficking Deficits	37
Targeting Sirtuin1 to treat aging-related tissue fibrosis: From prevention to therapy	37
Animal models of fibromyalgia: What is the best choice?	37
Branched and linear fatty acid esters of hydroxy fatty acids (FAHFA) relevant to human health	37
Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping	36
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy	35
Signal transducer and activator of transcription 3 signaling in tumor immune evasion	35
Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer	35
The roles of non-coding RNAs in vascular calcification and opportunities as therapeutic targets	35
The antidepressant actions of ketamine and its enantiomers	35
Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy	35
Gulf War Illness: Mechanisms Underlying Brain Dysfunction and Promising Therapeutic Strategies	35
The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance	34
The translational values of TRIM family in pan-cancers: From functions and mechanisms to clinics	34
Integrins in cancer: Emerging mechanisms and therapeutic opportunities	34
Emerging mechanisms contributing to mast cell-mediated pathophysiology with therapeutic implications	34
Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response	33
An update on human T-cell leukemia virus type I (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) focusing on clinical and laboratory biomarkers	33
Melanosome transport and regulation in development and disease	33
Therapeutic potential of sulfur-containing natural products in inflammatory diseases	33
CYP2J2 Molecular Recognition: A New Axis for Therapeutic Design	33
Indoleamine and tryptophan 2,3-dioxygenases as important future therapeutic targets	33
Recent advances in clinical trials targeting the kynurenine pathway	33
Lipopolysaccharide lipid A: A promising molecule for new immunity-based therapies and antibiotics	33
Mitochondrial metabolism mediated macrophage polarization in chronic lung diseases	32
Public health risks associated with chronic, low-level domoic acid exposure: A review of the evidence	32
DNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventions	32
Endothelial function and dysfunction: Impact of sodium-glucose cotransporter 2 inhibitors	32
The role of hypoxia-inducible factors in cardiovascular diseases	32
Statins in the treatment of depression: Hype or hope?	32
Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know	31

TLR4 biased small molecule modulators	31
Clozapine’s multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in tre	31
The IL-18/IL-18R1 signalling axis: Diagnostic and therapeutic potential in hypertension and chronic kidney disease	31
Transitional changes in the structure of C-reactive protein create highly pro-inflammatory molecules: Therapeutic implications for cardiovascular diseases	31
The pathophysiological function of non-gastrointestinal farnesoid X receptor	31
Resistance looms for KRAS G12C inhibitors and rational tackling strategies	30
Transcription factor GLIS3: Critical roles in thyroid hormone biosynthesis, hypothyroidism, pancreatic beta cells and diabetes	30
Targeting CXCR1 and CXCR2 receptors in cardiovascular diseases	30
A natural product solution to aging and aging-associated diseases	30
A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor	30
Novel insights into RIPK1 as a promising target for future Alzheimer’s disease treatment	29
The contribution of altered neuronal autophagy to neurodegeneration	29
Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation	29
Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities	29
New approaches for developing multi-targeted drug combinations for disease modification of complex brain disorders. Does epilepsy prevention become a realistic goal?	29
Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors	29
Cancer metastasis: Molecular mechanisms and clinical perspectives	29
Medicinal chemistry, pharmacology, and therapeutic potential of α-conotoxins antagonizing the α9α10 nicotinic acetylcholine receptor	28
Vitamin A in health care: Suppression of growth and induction of differentiation in cancer cells by vitamin A and its derivatives and their mechanisms of action	28
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors	28
Molecular mechanisms and therapeutic implications of tetrandrine and cepharanthine in T cell acute lymphoblastic leukemia and autoimmune diseases	28
Endothelial dysfunction as a complication of anti-cancer therapy	28
NRF2 in human neoplasm: Cancer biology and potential therapeutic target	28
Extracellular vesicle-based therapeutics: Extracellular vesicles as therapeutic targets and agents	28
Nitrite and myocardial ischaemia reperfusion injury. Where are we now?	28
Clinical advances in oncolytic virotherapy for pediatric brain tumors	28
Target identification and validation of natural products with label-free methodology: A critical review from 2005 to 2020	28
Recent advances in studies of SLCO2A1 as a key regulator of the delivery of prostaglandins to their sites of action	28
Cocaine use disorder: A look at metabotropic glutamate receptors and glutamate transporters	27
The role of the brain renin-angiotensin system (RAS) in mild traumatic brain injury (TBI)	27
Efficacy and mechanism of actions of natural antimicrobial drugs	27
CNS border-associated macrophages in the homeostatic and ischaemic brain	27
The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors	26
Addiction and the kynurenine pathway: A new dancing couple?	26
Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment	26
Pharmacological prevention of intimal hyperplasia: A state-of-the-art review	26
Molecular mechanisms and cardiovascular implications of cancer therapy-induced senescence	26
The cardiovascular effects of air pollution: Prevention and reversal by pharmacological agents	26
Advances in the pathophysiology of atopic dermatitis revealed by novel therapeutics and clinical trials	26
Transport function, regulation, and biology of human monocarboxylate transporter 1 (hMCT1) and 4 (hMCT4)	25
Targeting hedgehog signaling in pancreatic ductal adenocarcinoma	25
Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception	25
Two-pore and TRPML cation channels: Regulators of phagocytosis, autophagy and lysosomal exocytosis	25
Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences	25
MAS-related G protein-coupled receptors X (MRGPRX): Orphan GPCRs with potential as targets for future drugs	25
The evolving obesity challenge: targeting the vagus nerve and the inflammatory reflex in the response	25
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain	25
Exploring the “Other” subfamily of HECT E3-ligases for therapeutic intervention	25
A pan-cancer-bioinformatic-based literature review of TRPM7 in cancers	25
Are the epigenetic changes predictive of therapeutic efficacy for psychiatric disorders? A translational approach towards novel drug targets	24
Bile acids and neurological disease	24
Extracellular vesicles in hepatology: Physiological role, involvement in pathogenesis, and therapeutic opportunities	24
Is depression the missing link between inflammatory mediators and cancer?	24
The adiponectin signalling pathway - A therapeutic target for the cardiac complications of type 2 diabetes?	24
Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): An updated review	24
Time is of the essence: Coupling sleep-wake and circadian neurobiology to the antidepressant effects of ketamine	24
Cellular mechanisms and recommended drug-based therapeutic options in diabetic cardiomyopathy	24
Trailblazing perspectives on targeting breast cancer stem cells	24
PET imaging of immune checkpoint proteins in oncology	24
RANKL as a key figure in bridging between the bone and immune system: Its physiological functions and potential as a pharmacological target	24
Potassium (K+) channels in the pulmonary vasculature: Implications in pulmonary hypertension Physiological, pathophysiological and pharmacological regulation	23
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy	23
Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature	23
Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions	23
The roles of N6-methyladenosine methylation in the regulation of bone development, bone remodeling and osteoporosis	23
Current and emerging therapies for neuroendocrine prostate cancer	23
Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential	23
Prognostic and predictive molecular biomarkers in advanced colorectal cancer	23
Novel molecular targets in gastric adenocarcinoma	23
Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases	23
Dysregulation of metabolic pathways in pulmonary fibrosis	23
Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid	23
Targeted treatment of alcoholic liver disease based on inflammatory signalling pathways	22
Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events	22
Multitasking bamboo leaf-derived compounds in prevention of infectious, inflammatory, atherosclerotic, metabolic, and neuropsychiatric diseases	22
Recent advances and future perspectives on carbohydrate-based cancer vaccines and therapeutics	22
Targeting monocytes/macrophages in fibrosis and cancer diseases: Therapeutic approaches	22
Biased agonism in drug discovery: Is there a future for biased 5-HT1A receptor agonists in the treatment of neuropsychiatric diseases?	22
Oligonucleotides as therapeutic tools for brain disorders: Focus on major depressive disorder and Parkinson's disease	22
The future of targeted kinase inhibitors in melanoma	22
Allosteric modulation of GPCRs: From structural insights to in silico drug discovery	22
New advances in pharmacoresistant epilepsy towards precise management-from prognosis to treatments	22
The role of osteoprotegerin (OPG) in fibrosis: its potential as a biomarker and/or biological target for the treatment of fibrotic diseases	22
Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines	22
Assay design and development strategies for finding Hsp90 inhibitors and their role in human diseases	22
The intricate interplay between HIFs, ROS, and the ubiquitin system in the tumor hypoxic microenvironment	22
Contribution of non-selective membrane channels and receptors in epilepsy	22
Long noncoding RNAs: Potential therapeutic targets in cardiocerebrovascular diseases	21
Novel treatments for autism spectrum disorder based on genomics and systems biology	21
Nicotine’ actions on energy balance: Friend or foe?	21
Sex-related differences in the pharmacological treatment of heart failure	21
The next frontier in ADME science: Predicting transporter-based drug disposition, tissue concentrations and drug-drug interactions in humans	21
Dissecting the relationship between antimicrobial peptides and mesenchymal stem cells	20
Neutrophil extracellular traps: A novel target for the treatment of stroke	20
Circular RNAs in cardiovascular diseases	20